Phuturdex › Diseases › Overweight
Drugs in development · updated 30 October 2026
Overweight: drugs in development
As of 30 October 2026 there are 247 active clinical trials (recruiting or ongoing, phases I–III) on 139 drugs for overweight. 115 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 115 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TirzepatideZepbound, Mounjaro | II–III | 30 | NCT07846865 |
| SemaglutideWegovy, Rybelsus | II–III | 24 | NCT07891156 |
| OrforglipronFoundayo® | III | 10 | NCT07790861 |
| MirikizumabOmvoh® | III | 2 | NCT06937099 |
| BupropionForfivo Xl®, Aplenzin® | III | 1 | NCT07806279 |
| Megestrol AcetateMegace Es®, Megace® | II–III | 1 | NCT05316493 |
| SufentanilDsuvia®, Sufenta Preservative Free® | III | 1 | NCT07844512 |
| MetforminRiomet Er®, Glumetza® | II | 4 | NCT06273072 |
| AcarbosePrecose® | II | 1 | NCT06993428 |
| EmpagliflozinJardiance | II | 1 | NCT07336797 |
| LisdexamfetamineArynta®, Vyvanse® | II | 1 | NCT06847399 |
| NicotineNicotrol®, Nicoderm Cq® | II | 1 | NCT06173778 |
| OrlistatAlli, Xenical® | II | 1 | NCT06993428 |
| AcetaminophenParacetamol, APAP | I | 8 | NCT07013643 |
| DigoxinLanoxin®, Lanoxicaps® | I | 4 | NCT07550816 |
Sorted by most advanced phase and number of active trials. Showing 15 of 24 drugs.
All 139 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Obesity 233 drugs
- Insulin resistance 41 drugs
- Type 2 diabetes 171 drugs
- Pediatric Obesity 11 drugs
- Obstructive sleep apnea 32 drugs
- Weight loss 26 drugs
- Metabolic disease 30 drugs
- Prader–Willi syndrome 5 drugs
- Arterial hypertension 119 drugs
- Endometrial neoplasm 298 drugs
- Non-alcoholic Fatty Liver Disease 68 drugs
- Prediabetes 18 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Overnutrition 5 drugs
- Nutrition disorder 10 drugs
- Human body weight 13 drugs
- Metabolic disease 30 drugs
- Glucose metabolism disease 12 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D050177 “Overweight”.